Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Urol
Главные авторы: Bibby, Becky A. S., Thiruthaneeswaran, Niluja, Yang, Lingjian, Pereira, Ronnie R., More, Elisabet, McArt, Darragh G., O’Reilly, Paul, Bristow, Robert G., Williams, Kaye J., Choudhury, Ananya, West, Catharine M. L.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2021
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247203/
https://ncbi.nlm.nih.gov/pubmed/34210300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-021-00856-x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы